Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy

Epilepsy Research

Volumn 104, Issue 1-2, 2013, Pages 151-157

  Salih, Muhannad R M ^a   Bahari, Mohd Baidi ^b   Shafie, Asrul Akmal ^c   Hassali, Mohamed Azmi Ahmad ^c   Al lela, Omer Qutaiba B ^d   Abd, Arwa Y ^a   Ganesan, Vigneswari M ^e  

^a Al Rasheed University College   (Iraq)

^b AIMST UNIVERSITY   (Malaysia)

^c SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^d INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^e HOSPITAL PULAU PINANG   (Malaysia)

Author keywords

Cost effectiveness analysis; Malaysia; Paediatrics; Structural metabolic epilepsy

Indexed keywords

ANTICONVULSIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; STRUCTURAL METABOLIC EPILEPSY; TREATMENT RESPONSE;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG MONITORING; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 84875542473     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.09.012     Document Type: Article

References (21)

1. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F. Methodological issues in estimating the cost of epilepsy. Epilepsy Res. 1999, 33:39-55.
2. Beran R.G. Economic analysis of epilepsy care. Epilepsia 1999, 40:19-24.
3. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., Van Emde Boas W., Engel J., French J., Glauser T.A., Mathern G.W. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
4. Bond C.A., Raehl C.L. Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy. Pharmacotherapy 2006, 26:1369-1378.
5. Dupont W.D., Plummer W.D. Power and sample size calculations: a review and computer program. Control. Clin. Trials 1990, 11:116-128.
6. Engel A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001, 42:796-803.
7. International Monetary Fund World Economic and Financial Surveys: World Economic Outlook Database 2009, International Monetary Fund, Washington, DC, Available:, (accessed 10.07.11) (online). http://www.imf.org/external/pubs/ft/weo/2009/01/weodata/index.aspx.
8. Mcinnes G.T. The value of therapeutic drug monitoring to the practising physician - an hypothesis in need of testing. Br. J. Clin. Pharmacol. 1989, 27:281-284.
9. Pachlatko C., Chisholm D., Meinardi H., Sander J.W. The economic impact of epilepsy. Epilepsy: A Comprehensive Textbook 2008, Lippincott Williams & Wilkins, Philadelphia. J. Engel, T.A. Pedley, J. Aicardi (Eds.).
10. Patsalos P.N., Berry D.J., Bourgeois B.F., Cloyd J.C., Glauser T.A., Johannessen S.I., Leppik I.E., Tomson T., Perucca E. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
11. Rane C.T., Dalvi S.S., Gogtay N.J., Shah P.U., Kshirsagar N.A. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br. J. Clin. Pharmacol. 2001, 52:193-195.
12. Schumacher G.E., Barr J.T. Therapeutic drug monitoring: do the improved outcomes justify the costs?. Clin. Pharmacokinet. 2001, 40:405-409.
13. Sculpher M.J., Pang F.S., Manca A., Drummond M.F., Golder S., Urdahl H., Davies L.M., Eastwood A. Generalisability in economic evaluation studies in health care: a review and case studies. Health Technol. Assess. 2004, 8:1-192.
14. Shakespeare A., Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998, 7:119-125.
15. Sjoqvist F. Interindividual differences in drug response: an overview. Variability in Drug Therapy 1985, Raven Press, New York. M. Rowland, L.B. Sheiner, J. Steimer (Eds.).
16. Spector R., Park G.D., Johnson G.F., Vesell E.S. Therapeutic drug monitoring. Clin. Pharmacol. Ther. 1988, 43:345-353.
17. The Ministry of Health Malaysia. February, 2011. Available: (accessed). http://hpp.moh.gov.my/v2/.
18. Touw D.J., Neef C., Thomson A.H., Vinks A.A. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther. Drug Monit. 2005, 27:10-17.
19. Touw D.J., Neef C., Thomson A.H., Vinks A.A. Cost-effectiveness of therapeutic drug monitoring: an update. EJHP Sci. 2007, 13:83-91.
20. Wagner T.H., Goldstein M.K. Behavioral interventions and cost-effectiveness analysis. Prev. Med. 2004, 39:1208-1214.
21. World Health Organization CHOosing Interventions that are Cost Effective (WHO-CHOICE): Cost-Effectiveness Thresholds 2005, World Health Organization, Geneva, Available:, (accessed 10.07.11) (online). http://www.who.int/choice/costs/CER_levels/en/index.html.